Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
71 hedge funds and large institutions have $130M invested in Taro Pharmaceutical Industries Ltd. in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 27 reducing their positions, and 10 closing their positions.
1% less funds holding
Funds holding: 72 → 71 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
13% less capital invested
Capital invested by funds: $150M → $130M (-$20.1M)
30% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 27
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.81M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$892K |
| 3 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$621K |
| 4 |
BlackRock
New York
|
+$491K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$399K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.29M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.18M |
| 3 |
V
Veritable
Wilmington,
Delaware
|
-$544K |
| 4 |
HF
HRT Financial
New York
|
-$527K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$425K |
TARO Hedge Fund Activity: Q3 2022 in Review
71 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q3 2022, worth a combined $130M — down 13% from $150M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TARO and 9 opened new positions — a net loss of 1 holder — while 27 trimmed existing stakes and 19 added.
The largest buyer was Armistice Capital, adding an estimated $2.81M. The largest seller was Renaissance Technologies, cutting an estimated $1.29M.
- 71 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q3 2022, down from 72 in Q2 2022.
- Funds reported $130M of Taro Pharmaceutical Industries Ltd. stock for Q3 2022, down 13% quarter-over-quarter.
- 9 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q3 2022 and 10 closed out, a net change of -1 holder.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q3 2022 was Armistice Capital, an estimated $2.81M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q3 2022 was Renaissance Technologies, an estimated $1.29M sold.
Based on aggregated 13F filings for Q3 2022.